Results 111 to 120 of about 2,749 (135)

Tenofovir

Reactions Weekly
  +5 more sources

Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate

Clinical Gastroenterology and Hepatology, 2022
Yoon Jun Kim, Young-Suk Lim, Byung Chul Yoo   +2 more
exaly  

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B

Liver International, 2022
Young-Suk Lim, Jihye Lim, Kang Mo Kim
exaly  

Tenofovir Disoproxil Fumarate

Clinical Pharmacokinetics, 2012
Jaymin Shāh, Brian P Kearney
exaly  

Tenofovir

Reactions Weekly, 2007
openaire   +2 more sources

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

Journal of Antimicrobial Chemotherapy, 2019
Marta Boffito, Anton Pozniak, Charles Flexner   +2 more
exaly  

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection

Drugs, 2016
Sarah L Greig
exaly  

Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.

Clinical Infectious Diseases, 2015
Heidi Kalkwarf, Julia W Wu, Lynne Mofenson   +2 more
exaly  

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Lancet, The, 2020
Moupali Das, Kenneth Hugh Mayer, Robert Grant   +2 more
exaly  

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Lancet, The, 2015
Daniel Podzamczer, Paul E Sax, Scott McCallister   +2 more
exaly